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Low-grade endometrial stromal sarcomas (LGSSs) are rare,
accounting for about 0.2% of all genital tract malignancies (Koss
et al, 1965), and occur predominantly in premenopausal women
(Evans, 1982). Treatment of LGSSs is primarily surgical, and a
positive correlation between extent of surgery and recurrence 
or metastasis has been reported (Krieger and Gusberg, 1973;
Gadducci et al, 1996). Recurrences develop in one-third to one-
half of patients (Chang et al, 1990; Clement, 1993) and can appear
as long as 30 years after initial therapy (Doran, 1908; Gloor, 1982;
Styron, 1989). The role of adjuvant radiation and chemotherapy is
poorly defined (Gadducci et al, 1996).
Case reports and several small series have shown that uterine
and extrauterine LGSSs can express oestrogen receptors (ER) and
progesterone receptors (PR) (Gloor et al, 1982; Baker et al, 1984;
Piver et al, 1984; Lantta et al, 1984; Sutton et al, 1986; Katz et al,
1987; Keen and Philip, 1989; Tosi et al, 1989; Dunton et al, 1990;
Navarro, 1992; Sabini et al, 1992; Fukunaga et al, 1997, 1998) and
are sensitive to sex steroid hormones (Pellillo, 1968; Baggish and
Woodruff, 1972; Krumholz et al, 1973; Gloor et al, 1982; Baker et
al, 1984; Lantta et al, 1984; Piver et al, 1984; Tsukamoto et al,
1985; Katz et al, 1987, Keen and Philip, 1989; Montag and
Manert, 1989; Rand and Lowe, 1990; Navarro et al, 1992;
Scribiner and Walker, 1998). These observations have been based
on biochemical examinations and have not been confirmed in a
larger patient cohort. Immunohistochemical quantification of ER
and PR, as performed routinely in breast carcinoma, has not been
reported for LGSSs.
In the present study we analysed ER and PR expression in a
retrospective series of 21 LGSSs. We used the Remmele scoring
system (Remmele and Schicketanz, 1993) to quantify ER and PR
expression at the cellular level.
PATIENTS AND METHODS
Twenty-one LGSSs originating between 1983 and 1998 were
retrieved from the archives of the Departments of Obstetrics and
Gynecology and Pathology of the University of Graz, Austria.
Haematoxylin and eosin (H&E)-stained sections were re-evalu-
ated by two pathologists (SR and OR) and staged according to 
the guidelines of the 1994 WHO classification of tumours of 
the female genital tract (Scully et al, 1994). All tumours were
composed of cells resembling normal endometrial stromal cells
and invaded the myometrium and usually its vascular spaces.
Mitoses were fewer than 10/10 high-power fields (HPF = objec-
tive ´ 40) and necrosis was absent. The International Federation of
Gynecology and Obstetrics (FIGO) stage for endometrial carci-
noma was adapted for LGSS (stage I, tumours limited to the
uterus; stage II, involvement of the cervix; stage III, involvement
of the pelvis; and stage IV, disease outside the pelvis).
For quantitative immunohistochemical analysis one or two
paraffin blocks with representative portions of the tumours were
selected and 4-mm thick sections were stained with antibodies 
to ER (monoclonal, NCL-ER-6F11, Novocastra, UK) and PR
(monoclonal, NCL-PGR-1A6, Novocastra, UK). The peroxidase-
antiperoxidase method was used to detect the antigens. ER and PR
expression was scored by two pathologists (SR and OR) with a
scoring system based on both the percentage of positive tumour
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1993). The percentage of positive tumour cell nuclei was esti-
mated on a four-tiered scale (< 10% = 1, 11–50% = 2, 51–80% = 3,
>81% = 4). A four-tiered scale was also used to score the staining
intensity (negative = 0, weak = 1, moderate = 2, strong = 3). The
staining intensity was based on the predominant staining intensity
in the tumour. The final immunoreactive score was obtained by
multiplying the two scores. A final score of 0 was classified as
negative, 1–3 as low, 4–6 as moderate and 8–12 as high. Receptor-
positive breast carcinoma samples served as positive controls and
normal human serum as negative controls.
The mean age of the patients at surgery was 46 years (range
34–79) and only three patients were post-menopausal. Sixteen
patients had surgical stage I, four stage III and one stage IV
disease. The most common preoperative diagnosis was uterine
leiomyomas. Twenty patients underwent total abdominal hysterec-
tomy with bilateral salpingo-oophorectomy. One patient had only
exploratory laparotomy. Four patients (nos 2, 9, 14, 16) with stage
III disease additionally had an omentectomy and one patient (no.
16) underwent pelvic lymphadenectomy. Four patients (nos 2, 9,
12, 16) received adjuvant chemotherapy, one patient (no. 14)
received adjuvant radiation and 16 patients had no further treat-
ment. Four patients were lost to follow-up and the median follow-
up of the remaining 17 patients was 6.3 (1–14) years. All patients
were followed through the Department of Obstetrics and
Gynecology. Three patients (nos 7, 9, 16) developed pelvic recur-
rences and one patient (no. 10) had distant metastases in the lung
and bone. One patient (no. 7) with pelvic recurrences at 2 and 8
years after initial presentation was reoperated and material for
ER/PR determination was available. Two patients (nos 10, 14)
died of disease and one patient (no. 4) of unrelated causes. None of
the patients had hormonally active tumours or conditions such as
polycystic ovarian disease or hyperthecosis that might be respon-
sible for prolonged oestrogen stimulation of the endometrium
(Press and Scully, 1985).
RESULTS
Results are summarized in Table 1. ER and PR were strongly
expressed in the proliferative phase and early secretory phase of non-
tumour endometrial stroma of all premenopausal patients (Figure 1).
ER were seen in 15 (71%) and PR in 20 (95%) LGSSs respectively
(Figures 2–4). ER expression was scored as high in three (14%),
moderate in four (19%), and low in eight (38%) tumours. Six (29%)
LGSSs did not stain for ER, all of these tumours were positive for
PR. PR expression was scored as high in eight (38%), moderate in
ten (47%) and weak in two (10%) tumours. Only one (5%) LGSS did
not stain for PR (this tumour was positive for ER).
LGSSs with a high score for ER or PR were uniformly positive
throughout the tumour (Figure 2). LGSSs with a moderate score
demonstrated variable staining (Figure 3). In LGSSs with a low
score the majority of tumour cells were negative. The staining
intensity of the positive cells ranged from weakly to strongly posi-
tive (Figure 4). The patient (no. 7) with pelvic recurrences 2 and 8
years after initial surgery showed successive loss of ER expres-
sion. ER expression was moderate in the primary tumour, low in
the first recurrence, and absent in the second. PR expression was
high in the primary tumour and both recurrences.
DISCUSSION
This is the first quantitative immunohistochemical study of ER/PR
expression in LGSS. Most tumours expressed ER and PR, but
expression of both receptors varied widely ranging from negative
to strongly positive.
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Table 1 Expression of ER and PR in 21 patients with LGSS
Patient Age (at Stage Adjuvant Clinical ER ER Interpretation PR PR interpretation
No. presentation) (FIGO) therapy follow-up cells SI score (overall cells SI score (overall
expression) expression)
46 I None NED 1 1 1 Low 3 3 9 High
50 III CT Lost 1 2 2 Low 4 3 12 High
74 I None Lost 0 0 0 Negative 2 2 4 Medium
79 I None DWD 3 3 9 High 2 2 4 Medium
40 I None NED 3 3 9 High 2 3 6 Medium
39 I None Lost 2 2 4 Medium 2 2 4 Medium
44 I None NED 2 2 4 Medium 4 3 12 High
51 I None NED 1 1 1 Low 2 2 4 Medium
44 III CT AWD 4 3 12 High 4 3 12 High
35 IV None DOD 1 2 1 Low 0 0 0 Negative
38 I None NED 0 0 0 Negative 1 3 3 Low
35 I CT AWD 0 0 0 Negative 2 3 6 Medium
50 I None NED 1 1 1 Low 2 3 6 Medium
65 III RT DOD 1 2 2 Negative 2 2 4 Medium
45 I None NED 2 2 4 Medium 3 3 9 High
35 III CT AWD 1 1 1 Low 4 3 12 High
42 I None NED 0 0 0 Negative 1 2 2 Low
47 I None NED 0 0 0 Negative 2 3 6 Medium
34 I None Lost 1 1 1 Low 4 3 12 High
35 I None NED 1 1 1 Low 4 3 12 High
35 I None NED 2 2 4 Medium 2 3 6 Medium
CT: chemotherapy, RT: radiotherapy, NED: no evidence of disease, AWD: alive with recurrent disease, DWD: dead without disease, DOD:
dead of disease, Lost: lost to follow-up, Cells: percentage of positive tumour cell nuclei (< 10% = 1; 11–50% = 2; 51–80% = 3; > 81% = 4)
SI: staining intensity (negative = 0; weak = 1; moderate = 2; strong = 3), Score: Cells ´ SI, Interpretation: Score 1–3 as low; 4–6 as





















21Oestrogen and progesterone are important regulators of
endometrial stromal function and act by binding to their nuclear
receptors (Pickartz et al, 1990; Salmi et al, 1998). Most previous
studies of sex-steroid receptors in LGSSs were performed
biochemically and were based on fewer than five cases of LGSSs
(Baker et al, 1984; Lantta et al, 1984; Tsukamoto et al, 1985;
Sutton et al, 1986; Katz et al, 1987; Navarro et al, 1992). The
reported concentrations of ER in tumour tissue ranged from 0
(Katz et al, 1987) to 1628 (Sutton et al, 1986) and of PR from 0
(Dunton et al, 1990) to 1811 (Dunton et al, 1990) fmol mg–1
cytosol protein. However, cytosol-based biochemical methods 
are not highly specific (Helin et al, 1990). In breast carcinoma,
immunohistochemical methods appear more sensitive, as they
allow a better prediction of responsivness of the hormone therapy
(Robertson et al, 1992). In analogy to breast carcinoma, we were
able to demonstrate heterogeneous expression of ER and PR in
LGSSs on a cellular level, which suggests different levels of
susceptibility to hormonal therapy. Interestingly, in a patient with
recurrent disease expression declined successively with each
recurrence while PR expression remained high in both recur-
rences.
Several clinical observations suggest that LGSSs are sensitive
to sex-steroid hormones. Katz et al (1987) reported four complete
or partial responses with hormonal therapy. All four patients were
alive and free of disease or alive with stable disease 2–6 years after
initial diagnosis. Regression in size of metastases has been
reported after bilateral oophorectomy (Baggish and Woodruff,
1972) and radiation-induced castration (Gloor et al, 1982). A
lower incidence of recurrence and longer disease free intervals
after bilateral oophorectomy have also been reported (Krieger and
Gusberg, 1973). Recurrent disease has been successfully treated
with progestins (Pellillo, 1968; Baggish and Woodruff, 1972;
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Figure 1 ER expression in premenopausal nontumour endometrium,
proliferative phase. ER are present in the stroma and epithelium of the
glands. ER, peroxidase–antiperoxidase, original magnification ´ 100
Figure 3 LGSS with overall medium ER expression. Varying degrees of
nuclear staining in the entire specimen indicate heterogeneous receptor
expression (patient no. 6, score 4). PR, peroxidase–antiperoxidase, original
magnification ´ 250
Figure 2 LGSS with overall low PR expression. Only individual cells or
small groups of cells show strong nuclear staining while the majority of cells
do not stain (patient no. 17, score 2). PR, peroxidase–antiperoxidase,
original magnification ´ 250
Figure 4 LGSS with overall high PR expression with homogeneous strong
nuclear staining in the absence of cytoplasmatic staining (patient no. 7, score
12). PR, peroxidase–antiperoxidase, original magnification ´ 200Krumholz et al, 1973; Gloor et al, 1982; Baker et al, 1984;
Tsukamoto et al, 1985; Keen and Philip, 1989; Montag and
Manart, 1989; Rad and Lowe, 1990; Horowitz et al, 1996).
Scribiner and Walker (1998) reported preoperative treatment of
LGSS with progestins. Anecdotal experience by Horowitz et al
(1996) suggests that estrogen replacement therapy following a
total hysterectomy and bilateral salpingo-oophorectomy in
patients with LGSSs may increase the risk for recurrence. While
the majority of LGSSs have been shown to contain ER and PR, not
all responded to hormonal therapy. Sutton et al (1986) suggested
that a critical threshold concentration of sex-steroid receptor is
necessary for hormonal manipulation to be successful. The
number of patients in our series is too small to analyse for associa-
tions between receptor status, hormone treatment and recurrence.
The heterogeneous expression of ER and PR receptors in our
study may reflect receptor mutations with antigen loss and hetero-
geneous tumour populations (Richer et al, 1998). The number of
patients in our study is too low to speculate about any association
regarding clinical behaviour and receptor status. The three patients
with recurrence in our series varied widely in receptor expression.
Conceivably, patients with LGSS could benefit from hormonal
therapy based on the individual receptor status for primary and
recurrent disease. In analogy to breast carcinoma, anti-oestrogens
(Luo et al, 1997), selective anti-oestrogen receptor modulators
(Cummings et al, 1999), progesterone (Bernoux et al, 1998), anti-
progesterone (Eldar-Geva and Healy, 1998), aromatase inhibitors
(Miller et al, 1998) and luteinizing hormone-relasing hormone
analogues (GNRH-A) (Vignali and Genazzani, 1998) might be
useful in this setting. Hormone treatment might benefit patients
with advanced disease for preoperative down-staging (Scribiner 
et al, 1998) or palliation, patients with disease confirmed to the
uterus after hysterectomy, or patients with recurrence (Krumholz
et al, 1973; Gloor et al, 1982).
In conclusion, we suggest that, as in breast carcinoma, ER and
PR should be routinely quantified in LGSSs by immunohisto-
chemical methods.
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